Oncology
News from the FDA/CDC
FDA OKs sacituzumab govitecan for HR+ metastatic breast cancer
Label expansion for the Trop-2–directed antibody-drug conjugate was based on the TROPICS-02 trial.
Conference Coverage
Immunotherapy with antibiotics doesn’t worsen biliary tract cancer outcomes
Previous studies and clinical observations have suggested that antibiotics during immunotherapy treatment may hasten negative outcomes.
From the Journals
Race and geography tied to breast cancer care delays
A new study suggests that “treatment delays are alarmingly common in patients at high risk for breast cancer death, including young Black women...
Commentary
Commenting on weight’s not rude. It’s dangerous.
My awkward statement had been the first time anyone on campus had directly mentioned her weight, though she suspected that people were talking...
From the Journals
Black patients less likely to receive opioids for advanced cancer
Black patients were more likely to undergo urine drug screening despite being less likely to receive any opioids for pain management.
From the Journals
Loneliness risk elevated among young cancer survivors
Young cancer survivors were more than twice as likely to report loneliness at study baseline and follow-up.
News
FDA OKs elacestrant for ESR1+ advanced, metastatic breast cancer
The agency also approved the Guardant360 CDx assay as a companion diagnostic to identify breast cancer patients who meet the treatment...
From the Journals
Difficulty fitting family into career: Female oncologists
In a survey of female oncologists, 95% said their career plans were at least somewhat associated with the timing of when to start a family.
Feature
New cancer data spark outcry from patient advocates
The American Cancer Society on Jan. 13 revealed what it called ‘alarming’ news about prostate cancer.
From the Journals
Physician group issues 31 treatment recommendations for early-onset colorectal cancer
There was strong consensus that all individuals younger than 50 should undergo CRC risk stratification and prompt symptom assessment.
Conference Coverage
New ‘reference regimen’ in metastatic pancreatic cancer?
NALIRIFOX regimen can be considered new reference regimen for first-line pancreatic cancer treatment, a researcher reports at ASCO GI.